🚨Come & join us in our exciting programme of Radiotherapy-related research @TheChristieNHS . Lead radiographer-led research. Get in touch @MCRCnews @ESTRO_RT @SCoRMembers @RT_physics #RTT
bmj.com/healthcareers/…

AI pathology may speed patient selection and make cancer-trial assessments more consistent. This review explains what it takes to reach patients: reliable tissue data, connected lab systems and validation across hospitals.

bmjoncology.bmj.com/content/5/2/e0…

Cancer trials should fit patients' lives. A BMJ Oncology editorial calls for flexible remote, local or hospital visits to reduce burden and improve access.

@angelacwebster @JiaJennyLiu

bmjoncology.bmj.com/content/5/2/e0…

Could cancer patients safely receive fewer doses of immunotherapy? A BMJ Oncology review explores ways to ease the burden on patients and health services while preserving treatment benefit.

bmjoncology.bmj.com/content/5/2/e0…

Presenting the UK’s SARON study Dr @fifimcdrmh to a full hall at #ESMO26

In patients with de novo oligometastatic mutation driver negative #NSCLC , consolidation radiotherapy to the primary and metastases improved PFS but no OS

No significant difference in QOL or AEs

Huge nts and trialists involved

Final day #RANZCR26 There's a great #FROGG session on bladder cancer Dr Ashutosh Dixit shares the #Christchurch experience of implementing #BCON 👏🏽🥳
Now all bladders have option of radiosensitisation @syeepei #WhereisHoskin @MCRCnews @RT_physics @RANZCRcollege @FacRadOncology

Ready for the #prostate session at #RANZCR26 🥳 @FacRadOncology @RANZCRcollege

#WhereisHoskin? @MSK_RadOnc Grand Rounds

A masterclass in #ProstateCancer HDR brachytherapy! 🎯

A pleasure to host Peter Hoskin at @MSKCancerCenter.
Thank you for sharing your expertise and sparking a terrific discussion! #RadOnc

Hello #RANZCR26 it's great to be here in beautiful sunny Christchurch. Looking forward to three days of meeting friends, making friends and exchanging ideas @MCRCnews @RCRadiologists @TheChristieNHS @RANZCRcollege @FacRadOncology

One month to go! ⏳
📆 11 November is the deadline to submit your abstract for #ESTRO27!
Present your #CancerResearch on a global stage, gain recognition, and benefit from joint #GreenJournal & @TheLancetOncol sessions.
👉 Submit now: bit.ly/4zvNufW
#Radonc #medphys #RTT

Every cancer organ gets the same sequence: surgery is the standard, then trials show you often don't need it, then surgery becomes the salvage.

Breast, larynx, limb, rectum, esophagus, mesothelioma.

Bladder is next. Patients want their organs. 🧵

Reviewer 2 strikes again...🤦🏽‍♀️

🧬 The ESTRO #Biology Committee is recruiting 1 new member:
📌 Help design the #ESTRO27 biology track
📌 Shape teaching courses & newsletter
📌 Champion early-career scientists
📅 Deadline: 8 Nov 2026
✅ Apply here: bit.ly/3WbuWmx
#RadOnc #Radiotherapy #RadBio

Applications are now open for our 2027 entry Cancer Research UK (CRUK)-funded PhD opportunities! 🧪 👩‍🔬

Interested in applying for a Clinical or Non-Clinical PhD? Explore our available projects: crukcentre.manchester.ac.uk/study/research…

📆 Deadline: Monday 23rd November 2026

We would love to host you for an #adaptive #radiotherapy fellowship if you're successful @CICEManchester @MCRCnews @RCRadiologists @ESTRO_RT 👏🏽
eso.net/education-and-…

People interested in #ClinOnc #ACFs - take a look at Manchester - recruiting from #ST3 @MCRCnews @OfficialUoM @CICEManchester @TheChristieNHS @RCRadiologists
Clinical Oncology ST3 2027 | Medical Hub share.google/VVUgLhTUASsHCf…

Could changes in local bacteria and immunity be to blame for the development of colorectal cancer? This new study examines this relationship.

bmjoncology.bmj.com/content/5/2/e0…

The @MCRCnews clinical & non-clinical PhDs are out - come and join us - there are some great projects for all interests. Lots of clinical projects for you budding researchers! @RCRadiologists 👇🏽
Research Opportunities - Cancer Research UK Manchester Centre share.google/YWnBFpJhglMOG5…

#ASTRO2026
What if radioresistance in bladder cancer is dynamic, shaped by tumor-intrinsic biology, hypoxia and the TME? @achoud72 presented pre-clinical work challenging this paradigm:
🔹Acquired resistance implicated RAD51C, VTN & MYL9
🔹Hypoxia screens identified STAMBP & YAP1 as poxic tumors showed substantial CNV burden, particularly on chr9
🔹3D tumor-like models are integrating matrix stiffness, tumor genomics & immune cells to better recreate RT response
@UroToday @ASTRO_org

Possibly the greatest moment of all television, of all time.